Immunotherapy with the novel investigational agent spliceosomal peptide P140 (IPP-201101; Lupuzor) safely improves the clinical and biological status of patients with systemic lupus erythematosus (SLE), according to results of an early phase II clinical trial. Reuters Health Information
A summary of currently available clinical guidelines from NICE which mention complementary and alternative medicine demonstrates some surprising omissions and lack of uniformity. International Journal of Clinical Practice
Endothelial progenitor cells (EPCs) are described to serve as a biomarker for CV risk. Since CV risk is seen in Systemic lupus erythematosus (SLE), would SLE be associated with altered EPC levels? Rheumatology
In this patient with severe multiple sclerosis (MS), oral cannabis compounds provided a significant reduction of pain and improved quality of life. Cases Journal
Rapidly progressive joint flexures are presented in a 58-year-old woman diagnosed with palmar fasciitis and polyarthritis syndrome associated with pancreatic carcinoma. Test your diagnostic acumen. Nature Clinical Practice Rheumatology
